SymBio Pharmaceuticals Limited (TYO:4582)

Market Cap	6.96B -14.4%
Revenue (ttm)	1.31B -46.7%
Net Income	-4.78B
EPS	-95.12
Shares Out	71.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	466,900
Average Volume	1,110,840
Open	98.00
Previous Close	97.00
Day's Range	96.00 - 98.00
52-Week Range	81.00 - 229.00
Beta	0.69
RSI	36.93
Earnings Date	May 7, 2026

About SymBio Pharmaceuticals

SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 91
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4582

Financial Performance

In 2025, SymBio Pharmaceuticals's revenue was 1.31 billion, a decrease of -46.70% compared to the previous year's 2.45 billion. Losses were -4.78 billion, 24.6% more than in 2024.